 NEW YORK , March 15, 2022 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX, an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Companys President and Chief Scientific Officer, will present recent clinical results today, Tuesday, March 15 th, at the International Conference on Alzheimers AD and Parkinsons Diseases ADPD 2022. The titled abstract, Neurotrophic Restoration for Neurodegenerative Disease summarizes therapeutic improvement by Bryostatin for advanced AD patients in placebo-controlled trials and its potential benefits for other neurodegenerative disorders such as Parkinsons Disease. 